Conn P J, Pin J P
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Annu Rev Pharmacol Toxicol. 1997;37:205-37. doi: 10.1146/annurev.pharmtox.37.1.205.
In the mid to late 1980s, studies were published that provided the first evidence for the existence of glutamate receptors that are not ligand-gated cation channels but are coupled to effector systems through GTP-binding proteins. Since those initial reports, tremendous progress has been made in characterizing these metabotropic glutamate receptors (mGluRs), including cloning and characterization of cDNA that encodes a family of eight mGluR subtypes, several of which have multiple splice variants. Also, tremendous progress has been made in developing new highly selective mGluR agonists and antagonists and toward determining the physiologic roles of the mGluRs in mammalian brain. These findings have exciting implications for drug development and suggest that the mGluRs provide a novel target for development of therepeutic agents that could have a significant impact on neuropharmacology.
在20世纪80年代中后期,有研究发表,首次证明了谷氨酸受体的存在,这些受体不是配体门控阳离子通道,而是通过GTP结合蛋白与效应系统偶联。自这些最初的报告以来,在表征这些代谢型谷氨酸受体(mGluRs)方面取得了巨大进展,包括克隆和表征编码八个mGluR亚型家族的cDNA,其中几个有多个剪接变体。此外,在开发新的高选择性mGluR激动剂和拮抗剂以及确定mGluRs在哺乳动物脑中的生理作用方面也取得了巨大进展。这些发现对药物开发具有令人兴奋的意义,并表明mGluRs为开发可能对神经药理学产生重大影响的治疗药物提供了一个新靶点。